Catalyst Dossier · compiled by CeliA 🧫

Innovent Biologics Inc/ADR (IVBXF)

Biotechnology · market cap $19.2B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-01 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Innovent Biologics (IVBXF) is a China-based biotechnology company with approximately 6,190 employees and a market cap of roughly $19.2B, trading near $10.30 per share. The company operates an exceptionally broad pipeline spanning oncology, metabolic disease, ophthalmology, and immunology, with multiple Phase 3 assets and a dense cluster of near-term catalysts concentrated in H2 2026 through early 2027. Key upcoming readouts include IBI362 (GLP-1/GIP class, Type 2 Diabetes), IBI306 (PCSK9 inhibitor, hypercholesterolemia), and IBI311 (Thyroid Eye Disease), each rated high importance by the catalyst tracker.

The catalyst path

2026-08-01 (est.)Phase 3 · IBI362imp 9/10
2026-08-30 (est.)Phase 2 · IBI302 8mg doseimp 7/10
2026-09-06 (est.)Phase 3 · IBI306imp 9/10
2026-09-24 (est.)Phase 2 · IBI362imp 7/10
2026-09-30 (est.)Phase 2 · Tirzepatideimp 7/10
2026-09-30 (est.)Phase 3 · Pemetrexedimp 9/10
2026-10-31 (est.)Phase 2 · IBI3003imp 7/10
2026-11-30 (est.)Phase 2 · Pemetrexedimp 7/10

Pipeline

Asset	Phase	Indication
Picankibart	Phase 3	Plaque Psoriasis
Febuxostat	Phase 3	Gout
IBI311 (20 mg)	Phase 2	Thyroid Eye Disease
Docetaxel	Phase 3	HER2-positive Breast Cancer
Low dose IBI302	Phase 2	Neovascular Age-related Macular Degeneration
IBI3003	Phase 2	Multiple Myeloma
Tirzepatide	Phase 2	Obesity
IBI112 dose 2	Phase 2	Psoriasis
PD1	Phase 2	Relapsed/Refractory Classical Hodgkin's Lymphoma
IBI301 plus CHOP	Phase 3	Diffuse, Large B-Cell, Lymphoma
IBI376	Phase 2	Indolent Non-hodgkin Lymphoma
IBI311	Phase 3	Thyroid Eye Disease
IBI363	Phase 2	Melanoma
IBI310	Phase 3	Advanced Cervical Cancer
IBI334	Phase 2	Advanced Solid Tumors
IBI130	Phase 2	Solid Tumor
IBI354	Phase 3	Locally Advanced Unresectable or Metastatic Solid Tumors
IBI129	Phase 2	Solid Tumor
IBI308	Phase 3	Esophageal Squamous Cell Carcinoma
IBI343,sintilimab,oxaliplatin,S-1	Phase 2	CLDN18.2 Positive

Price & technical context

3-month

-10.4%

6-month

-13.3%

12-month

+73.4%

52-wk range

$5.94–$13.76

vs 50-day MA

-4.2%

vs 200-day MA

-9.1%

Realized vol

64.3%

Max drawdown

-38.9%

Daily closes through 2026-05-18. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IVBXF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.